The benchmark SPDR S&P Biotech ETF (NYSEMKT: XBI) recently started to recover, but it's still down more than 33% from a peak it reached this February. Editas Medicine (NASDAQ: EDIT) shares are down a whopping 54% over the past three months. It's been falling harder than most biotech stocks this year thanks to disappointing clinical trial results for its lead candidate, EDIT-101.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting